You are here: Industry Insights > Ferring Pharmaceuticals

News List

Rebiotix, Ferring's microbiome-based therapy RBX2660 shows promise pharmatimes
May 07, 2020
Rebiotix and Ferring Pharmaceuticals have unveiled positive preliminary findings from an ongoing pivotal late-stage trial of the investigational microbiome-based treatment RBX2660.
Ferring Appoints Lead to New U.S. Oncology Division americanpharmaceuticalreview
January 25, 2019
Ferring Pharmaceuticals has appointed Sophie Opdyke, Pharm.D., MBA as Vice President, General Manager, Oncology, effective immediately. She most recently served as Vice President, Immuno-Oncology Lead at Pfizer.....
Ferring Pharmaceuticals adds two products to its robust reproductive health portfolio in the U.S. firstwordpharma
January 15, 2019
Ferring Pharmaceuticals (US) (Ferring) announced today an exclusive agreement to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd. (Sun Pharma).
Nocdurna Sublingual Tablets Now Available by Prescription in US americanpharmaceuticalreview
November 10, 2018
Ferring Pharmaceuticals announced the launch of Nocdurna (desmopressin acetate), the first and only sublingual tablet approved in the United States for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per ni
Ferring’s chief science officer to take over as executive board president in January fiercebiotech
November 02, 2018
Ferring Pharmaceuticals’ chief operating officer and president of its executive board, Michel Pettigrew, announced that he plans to retire Dec. 31.
MSD, Ferring complete clinical trial for Postpartum Haemorrhage biospectrumasia
March 05, 2018
Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide.
Ferring Pharmaceuticals acquires Apricus’ ex-US Vitaros assets and rights pharmaceutical-technology
March 10, 2017
Apricus Biosciences has completed the sale of its ex-US assets and rights related to Vitaros, a topical erectile dysfunction cream, to Ferring International Center.
Ferring Pharmaceuticals and Enteris BioPharma to develop an oral formulation of a Peptide-based Inje biospectrumasia
February 22, 2017
Enteris BioPharma will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product